Literature DB >> 29396853

Sweet syndrome associated with ipilimumab in a patient with metastatic melanoma.

N R Adler1,2, W K Murray3, B Brady3, C McCormack3, Y Pan1,2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29396853     DOI： 10.1111/ced.13399

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN： 0307-6938            Impact factor:   3.470


× No keyword cloud information.
  4 in total

Review 1.  Insights Into the Pathogenesis of Sweet's Syndrome.

Authors:  Michael S Heath; Alex G Ortega-Loayza
Journal:  Front Immunol       Date:  2019-03-12       Impact factor: 7.561

Review 2.  Management of immune checkpoint inhibitor-related dermatologic adverse events.

Authors:  Xiaoyan Si; Chunxia He; Li Zhang; Xiaowei Liu; Yue Li; Hanping Wang; Xiaoxiao Guo; Jiaxin Zhou; Lian Duan; Mengzhao Wang; Li Zhang
Journal:  Thorac Cancer       Date:  2019-12-09       Impact factor: 3.500

3.  "Skin rashes" and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management.

Authors:  Pietro Sollena; Simone Cappilli; Francesco Federico; Giovanni Schinzari; Giampaolo Tortora; Ketty Peris
Journal:  Hum Vaccin Immunother       Date:  2021-03-24       Impact factor: 4.526

Review 4.  [Management of Dermatologic Toxicities Related to Immune Checkpoint Inhibitors].

Authors:  Xiaoyan Si; Chunxia He; Li Zhang; Xiaowei Liu; Yue Li; Hanping Wang; Xiaoxiao Guo; Jiaxin Zhou; Lian Duan; Li Zhang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2019-10-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.